Cellectar Biosciences, Inc. (CLRB) vs Obsidian Therapeutics Inc. (OBX)

A side-by-side comparison of Cellectar Biosciences, Inc. and Obsidian Therapeutics Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

CLRB

Cellectar Biosciences, Inc.

$13M

$1.60HealthcareDelayed quote: Oct 6, 2026, 12:54 PM EDT

OBX

Obsidian Therapeutics Inc.

$14M

$13.62HealthcareDelayed quote: Oct 6, 2026, 12:55 PM EDT

Total return — CLRB vs OBX

growth of $100 · dividends reinvested · last 1y

CLRB +0.0% (+0.0%/yr)OBX -20.9% (-20.9%/yr)CLRB compounded faster over this window

CLRB OBX

Metrics side by side

Total return (annualized)

Metric	CLRB	OBX
Total return (1Y)	-49.83%	N/A
Total return CAGR (3Y)	-69.12%	N/A
Total return CAGR (5Y)	-60.51%	N/A
Total return CAGR (10Y)	-55.35%	N/A

OBX is an index fund, so valuation, profitability, and per-company growth metrics don't apply — the head-to-head here is total return (price plus reinvested dividends).

Go deeper

Full CLRB analysis Full OBX analysis Interactive comparison tool

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.